Novel Blood Biomarkers for Early detection of Alzheimer Disease
Genetic and epigenetic mitochondrial panel to predict the risk of progression to Alzheimer Disease (AD) in diagnosed mild cognitive impairment patients (MCI).
Novel diagnostic tool using blood samples of MCI.
The goal would be to develop cheap, fast and nonpainful methods to be used in this first stage of detection in primary care, hospitals and private medical assurances. Focused as middle age prevention plan, the early susceptibility detection would allow fast intervention to diminish the progression of the disease, improve patient’s quality of life and minimize associated direct and indirect cost for health systems and families. The technology should be easily introduced in mature as well as in emerging pharmaceutical markets.